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Abstract:  Tanapoxvirus (TPV) is a member of the genus Yatapoxvirus in the family Poxviridae and is endemic to 
equatorial Africa. This disease is restricted to human and non-human primates, producing a mild febrile illness 
characterized by a single or more rarely additional pock-like lesions on the extremities. While there are several studies 
elucidating the replication cycle and host range of TPV, there is currently no standardized investigation comparing the 
ability of TPV to successfully replicate in a variety of tumor cell lines. This study examined the cytopathic effect and 
calculated the efficiency of TPV replication in vitro using 14 different human cancer cell lines. TPV replicates efficiently 
in some human tumor cells, and is restricted in others when measured by viral titer at 7 days post infection. Results 
described here clearly demonstrate that TPV replication in one glioblastoma cell line (U-373), and one colorectal cancer 
cell line (HCT-116) is more productive than in owl monkey kidney cells (OMK). Replication in two renal cancer cell lines 
(ACHN and Caki-1) is also increased when compared to OMK. TPV infection produced the greatest change in cellular 
morphology in U-373 cells, and to a much lesser degree in the breast cancer cell lines T-47D and MCF-7, and in the 
ovarian cancer line SK-OV3. Negligible change was noted in glioblastoma line U-87, breast cancer line MDA-MB-435, 
osteosarcoma line HOS, melanoma line SK-MEL5, colorectal cancer line COLO205, and prostate cancer line PC3. The 
cell lines least permissive to TPV replication were the glioblastoma (U-87) and melanoma (SK-MEL5) cell lines. 
Keywords: Tanapoxvirus, poxvirus, yatapoxvirus, glioblastoma, cell culture. 
INTRODUCTION 
  Tanapoxvirus (TPV) was first described as the causative 
agent in two consecutive outbreaks among the Wapakomo 
tribe in 1957 and 1962 in the Tana River Valley, Kenya [1]. 
The virus was isolated during the 1962 outbreak, which 
affected over 50 people, and investigations conducted in 
Liverpool confirmed that it was a previously uncharacterized 
poxvirus [1]. Both outbreaks coincided with severe and 
extended flooding of the Tana River, eliciting a hypothesis 
that TPV infection is a zoonotic disease transmitted by 
mosquitoes or other blood-feeding insect vectors. Later 
incidences of TPV cases in Zaire affecting riverine natives 
supported this hypothesis [2]. 
  Patients infected with TPV sometimes suffered from a 
low-grade fever that lasted for 2-4 days [2]. The formation of 
one and rarely more pock-like skin lesions occurred after this 
short febrile illness. In the majority of cases, the 
development of a 1.0 cm in diameter papule on the 
extremities was raised, necrotic and contained no liquid 
unlike the pustular lesions of monkeypox [1, 2]. Regional 
lymphadenopathy also developed by the end of the first 
week of infection. In the following week, the papule 
ulcerated but never spread to more than 2.0 cm in diameter. 
The infection usually resolved within 6 weeks, when the 
ulcer heals and a scar forms and disappears at the site of 
ulceration, with little discomfort reported by patients. 
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  TPV is classified in the family Poxviridae,  and is a 
member of the genus Yatapoxvirus [3]. There are two species 
in this genus officially recognized by the International 
Committee for Taxonomy of Viruses (ICTV), TPV, and 
Yaba monkey tumor virus (YMTV) [4]. Yaba-like disease 
virus (YLDV) is over 98% similar in terms of genomic 
homology to TPV and is considered a strain of TPV [5, 6]. 
Outbreaks of what is now termed YLDV [7] occurred in 
several primate facilities in the United States in 1965 and 
1966 when an initial infection that affected several monkey 
species spread to their human handlers [8-10]. Subsequent 
investigations revealed that YLDV and TPV have the same 
host range and produced the same lesions in susceptible 
animals [8]. 
  Morphologically, TPV measures between 250 and 300 
nm in size and is similar to the prototypical member of the 
orthopoxvirus genus, vaccinia virus (VV) [11]. These large 
brick-shaped virions come in two distinct infectious forms, 
the intracellular mature virion (IMV) and extracellular 
enveloped virion (EEV). The majority of virions exist in the 
enveloped form [3]. In vitro, the replication cycle of TPV 
ranges from 36 to 48 hours depending upon the multiplicity 
of infection [12]. This is significantly slower than the 24 
hour replication cycle of VV [13]. TPV contains 144,565 
base pairs in its linear double-stranded DNA genome that 
was fully sequenced in 2007 [14]. TPV carries out DNA 
replication in specific areas of the cytoplasm of the host cell, 
assembling its new IMV particles in viral factories. The 
DNA genome of poxviruses contains inverted terminal 
repetitions (ITR), and is connected by hairpin loops [11]. 
The central region of the poxvirus genome is highly 
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termini tend to contain virulence and host-range genes that 
may be species-specific [5]. The host ranges of YLDV and 
TPV have been evaluated in a variety of cell lines of animal 
origin, as well as in live animals. Neither TPV nor YLDV 
replicate in chick embryo fibroblasts, primary and 
continuous rabbit kidney cells, bovine kidney cells, nor do 
they cause any lesions in mice, hamsters, and guinea pigs [1, 
8, 10]. There has been one report that YLDV caused lesions 
on German checker rabbits, but it does not cause the same 
effect in New Zealand white rabbits [10]. YLDV does not 
cause any cytopathic effect in adult rabbit cell lines [8]. 
Nevertheless, TPV has been shown to replicate in rat lung 
cells [12]. Currently, there are no studies that evaluate the 
susceptibility of different human cancer cell lines to TPV in 
a standardized protocol. TPV has been cultured in several 
human cell lines such as primary human dermal fibroblasts, 
primary human peripheral blood mononuclear cells, primary 
human thyroid, amnion, and human fetal lung cells, and 
several human cancer cells such as human epidermoid 
carcinoma and cervical cancer [1, 8, 12, 15]. The long-term 
objective of these studies is to evaluate the oncolytic 
potential of this virus in an animal model employing nude 
mice. Here we report the differential susceptibility of 14 
different human cancer cell lines to TPV infection. 
MATERIALS AND METHODOLOGY 
Virus, Cell Culture and Reagents 
  TPV expressing the enhanced green fluorescent (eGFP) 
gene was a gift from Dr. Grant McFadden at the University 
of Florida, Gainesville, Florida. The eGFP was inserted 
between ORF 5L and ORF 6L of TPV-Kenya and is 
regulated by a synthetic early/late promoter as described by 
Nazarian  et al. [15]. Owl monkey kidney (OMK), human 
glioblastoma (U-87, U-373, U-118), and human breast 
cancer (T-47D) cells were obtained from the American Type 
Culture Collection, Rockville, Maryland. Human 
osteosarcoma (HOS), human renal cell cancer (Caki-1, 
ACHN), human ovarian cancer (SK-OV3), human breast 
cancer (MCF-7, MDA-MB 435), human prostate cancer 
(PC3), human colorectal cancer (COLO205, HCT-116), and 
human melanoma (SK-MEL5) cell lines were also a gift 
from Dr. Grant McFadden. OMK cells were cultured in 
Eagle’s minimum essential medium (EMEM) purchased 
from Sigma, (St. Louis, MO), and supplemented with 10% 
(v/v) newborn calf serum (NBCS) from Life Technologies, 
(Grand Island, NY), 1.5g/L sodium bicarbonate, 2mM L-
glutamine, and antibiotics (penicillin G sodium 100 units/ml, 
and streptomycin sulfate 100g/ml) from Invitrogen 
(Carlsbad, CA) (growth medium). Infected cell monolayers 
were maintained in EMEM supplemented with 2% (v/v) 
NBCS, 1.5g/L sodium bicarbonate, L-glutamine, and 
antibiotics (maintenance medium). U-87, U-373, U-118, and 
T-47D cells were cultured in EMEM supplemented with 
10% (v/v) fetal bovine serum (FBS) purchased from Life 
Technologies, (Grand Island, NY), 1.5g/L sodium 
bicarbonate, 2mM L-glutamine, and antibiotics (penicillin G 
sodium 100 units/ml, and streptomycin sulfate 100g/ml) 
purchased from Invitrogen (Carlsbad, CA) (growth medium). 
Infected cell monolayers were maintained in EMEM 
supplemented with 2% (v/v) FBS, 1.5g/L sodium 
bicarbonate, L-glutamine, and antibiotics (maintenance 
medium). HOS, MCF-7, COLO205, HCT-116, ACHN, SK-
MEL5, MDA-MB 435, and Caki-1 cells were cultured in 
Dulbecco’s (modified Eagle medium DMEM) (Gibco) 
supplemented with 10% (v/v) FBS, 1.5g/L sodium 
bicarbonate, 2mM L-glutamine, and antibiotics (growth 
medium). Infected cell monolayers were maintained in 
DMEM supplemented with 2% (v/v) FBS, 1.5g/L sodium 
bicarbonate, L-glutamine, and antibiotics (maintenance 
medium). SK-OV3 was cultured in McCoy's 5a medium 
(ATCC) supplemented with 10% (v/v) FBS, 2.2g/L sodium 
bicarbonate, 2mM L-glutamine, and antibiotics (growth 
medium). Infected cell monolayers were maintained in 
McCoy’s 5a medium supplemented with 2% (v/v) FBS, 
1.5g/L sodium bicarbonate, L-glutamine, and antibiotics 
(maintenance medium). PC3 was cultured in F-12K medium 
(ATCC) supplemented with 10% (v/v) FBS, 1.5g/L sodium 
bicarbonate, 2mM L-glutamine, and antibiotics (growth 
medium). Infected cell monolayers were maintained in F-
12K medium supplemented with 2% (v/v) FBS, 1.5g/L 
sodium bicarbonate, L-glutamine, and antibiotics 
(maintenance medium). All cell lines were incubated at 37˚C 
in a humidified atmosphere of 95% air and 5% CO2 unless 
otherwise noted. 
Virus Quantitation 
  Approximately 1 x 10
5 TPV virions expressing eGFP 
(TPV-GFP) in 600 L maintenance medium were inoculated 
into 25 cm
2 monolayers of each cancer cell line. The virus 
was allowed to adsorb for 1 hour at room temperature on a 
rocking platform before non-adherent virus in the 
maintenance medium was aspirated out. Fresh maintenance 
medium was then added and each flask was incubated at 
37°C for 7 days. Infected monolayers were subjected to three 
cycles of freeze-thawing to release all viral particles into the 
medium. This infected medium was then serially diluted and 
titrated in duplicates, onto confluent monolayers of OMK 
cells cultivated in 6-well dishes, using 200 L dilutions of 1 
to 10
-6. The virus was allowed to adsorb for 1 hour at room 
temperature before the addition of overlay medium (mainte-
nance medium containing 0.5% (w/v) methylcellulose 4000 
centipoises (Fisher Scientific, NJ) and incubated at 37° C for 
10-15 days. Once viral plaques were visible under the 
microscope, the medium was then removed from the wells 
and the monolayer was stained with 0.1% (w/v) crystal violet 
in 10% formaldehyde (plaque staining solution). The 
monolayer stained for 20 minutes, rinsed in deionized water 
and air-dried. The average number of plaques was counted to 
determine the total yield of virus recovered from the infected 
flask. 
Visualization of Cells 
  At 7 days post infection, infected and uninfected cells in 
well plates were visualized using a Nikon Diaphot 300 
epifluorescence microscope under bright light or through a 
B2A filter cube (450 to 490 nm excitation band and 520 rim 
barrier filter). All photographs were taken using a 35 mm 
camera and processed through the Metamorph Image 
Analysis software from Molecular Devices (Downingtown, 
PA). 
RESULTS 
  The ability of TPV-GFP to replicate in and destroy 
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cancer cell lines. TPV-GFP was inoculated into breast cancer 
cells (T47D, MCF-7, MDA-MB-435), glioblastoma cells (U-
87, U-373, U-118), osteosarcoma cells (HOS), melanoma 
cells (SK-MEL5), ovarian cancer cells (SK-OV-3), renal 
cancer cells (ACHN, Caki-1), colorectal cancer cells 
(COLO205, HCT-116), and prostate cancer cells (PC3). 
OMK cells were used as a control. Complete viral titers are 
listed in Table 1. The images in Fig. (1)  show TPV-GFP 
infected control cells (OMK) and cancer cells under visible 
and ultra violet light at 7 days post infection (dpi). 
Table 1.  Titer of TPV-GFP from Infected Cancer Cell Lines 
at 7 Days Post Infection 
 
Cell Lines  Total Virus  
Yield in 5 ml 
Control (Owl Monkey Kidney) cells  OMK  1.0125 x 10
6 
T47D  7.25 x 10
4 
MCF-7  1.7375 x 10
5  Human Breast Cancer Cells 
MDA-MB-435  5.25 x 10
5 
U-118  2.875 x 10
5 
U-373  2.25 x 10
7  Human Glioblastoma Cells 
U-87  4.375 x 10
3 
Human Osteosarcoma Cells  HOS  5.5 x 10
4 
Human Melanoma Cells  SK-MEL5  4.25 x 10
3 
Human Ovarian Cancer Cells  SK-OV-3  1.9625 x 10
5 
ACHN  7.75 x 10
6 
Human Renal Cancer Cells 
Caki-1  4.0 x 10
6 
COLO205  4.5 x 10
4 
Human Colorectal Cancer Cells 
HCT-116  1.05 x 10
7 
Human Prostate Cancer Cells  PC3  6.5 x 10
4 
Cells were grown in 25 cm
2 flasks to confluency and each flask was infected with 
approximately 1 X 10
5 pfu. Infected flasks were incubated at 37° C for 7 days, and total 
virus yield was quantitated as described in Materials and Methods. 
 
  TPV-GFP replicated poorly in T47D and MCF-7 cells 
compared to OMK cells. There was a 14-fold and 6-fold 
reduction in number of virus particles retrieved from T47D 
and MCF-7 respectively, while MDA-MB-435 produced a 2-
fold reduction in viral particles when compared to OMK 
cells. Green fluorescence observed in T47D and MCF-7 is 
predictably less than in OMK cells. Cytopathic effect (CPE) 
in T47D and MCF-7 was less pronounced than CPE 
observed in OMK cells. There was no eventual destruction 
of cells, and T47D and MCF-7 monolayers remained intact 
even after two weeks. There was no identifiable CPE 
observed in virus infected MDA-MB-435 monolayer. 
  TPV-GFP replicated poorly in U-118 and U-87 when 
compared to OMK cells, with a 3.5-fold reduction in U-118 
cells, and a dramatic 231-fold reduction in viral replication 
in U-87 cells. In contrast, replication in U-373 surpassed 
replication in OMK by 22-fold. Replication in U-373 cells 
was the most productive among all 14 cell lines tested. CPE 
was observed in U-118 and U-373 cells, but not at all 
discernable in U-87 cells. Green fluorescence was noted to 
also be present within U-87 neurospheres despite the lack of 
visible CPE. TPV infected U-373 cells exhibited the most 
pronounced CPE where entire infected cell monolayers 
detached completely from the surface of the flask. 
  TPV-GFP produced 18-fold less virus particles in 
osteosarcoma cells (HOS) compared to OMK. There was 
observable CPE in the HOS infected monolayer, but no 
plaques were formed at 7 days. No further progression of 
CPE was noted beyond the initial infected area seen in Fig. 
(1). 
  In melanoma (SK-MEL5) cells, there was a 238-fold 
decrease in average number of viral particles recovered. 
There was no truly distinct CPE observed in infected SK-
MEL5 cells, and no plaques formed. The cell monolayer also 
remained intact well beyond 7 days post inoculation. SK-
MEL5 cells were the least suitable host for TPV-GFP 
replication among all cell lines tested. 
  TPV-GFP in ovarian cancer cells (SK-OV-3) suffered a 
5-fold reduction compared to that obtained from OMK cells. 
Infected SK-OV-3 cells appeared to become larger, flatter in 
appearance, more granular, and appeared darker in color, 
than uninfected SK-OV-3 cells. TPV-GFP yielded higher 
titers in the renal cancer cell lines tested compared to OMK 
cells at 7 days post infection. 
  The average viral replication of TPV-GFP in ACHN cells 
was more than 7-fold greater than OMK cells, while the 
average replication in Caki-1 cells was nearly 4-fold greater 
than in OMK cells. There was a drastic change in cellular 
morphology of virus infected ACHN and Caki-1 
monolayers. When the uninfected ACHN monolayer was 
fully confluent, infected ACHN monolayers had prominent 
CPE. The infected ACHN monolayer developed bright green 
foci under UV light, while areas of destroyed cells were seen 
as large clearings. Infected cells also become stretched, 
similar to that seen in a later stage of infected OMK cells. 
On the other hand, infected Caki-1 cells became more 
spherical and spread out, from the original spindle-like shape 
of tightly packed uninfected confluent monolayers. An 
increase in cellular debris in infected Caki-1 cell medium 
also indicated that cell death occurred, causing detachment 
of cells from the surface of the flask, and subsequently 
reducing the number of cells observed. 
  There was an interesting difference between two lines of 
human colorectal cells examined. While the average 
replication of TPV-GFP in COLO205 cells was close to 23-
fold lower than in OMK cells, replication in HCT-116 cells 
was more than 10-fold greater compared to OMK cells. 
COLO205 cells are semi-adherent in cell culture, and have 
varied cell morphology. The TPV-GFP infected COLO205 
cells did not exhibit a noticeable change in cell morphology 
under visible light. HCT-116 cells, on the other hand, did 
show significant CPE at 7 days post inoculation. Viral 
plaques were clearly seen in infected HCT-116 monolayers, 
and some cells do develop the stretched cell morphology 
seen in OMK and ACHN cells. 
  TPV-GFP replication in prostate cancer (PC3) cells was 
almost 16-fold less than replication in OMK cells at 7 days 
post infection. There was no discernable CPE observed in 
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change in cellular morphology. There was also no 
progression of green fluorescence beyond those initially 
recorded at day 7, suggesting that viral replication was 
aborted in PC3 cells. 
DISCUSSION 
  The ultimate aim of this study is to develop an oncolytic 
TPV that will be able to replicate in a variety of human 
cancer cells and drastically less or none at all in normal 
human cells. The results presented here demonstrate that 
TPV-GFP replicated well in several human cancer cell lines. 
Cytopathic effect was clearly observed in glioblastoma cell 
lines U-373 and U-118, renal cancer lines ACHN and Caki-
1, and colorectal cancer line HCT-116. Virus replication 
proceeded much faster in human cancer cells and also virus 
infection spread more quickly when compared to virus 
infection in OMK cells. Infected U-373 monolayers were 
completely destroyed and all infected cells detached from the 
surface of the culture flask within 7 days. There was a 
change in cellular morphology in breast cancer cell lines T-
47D and MCF-7, and to a lesser extent in the ovarian cancer 
line SK-OV3. Lastly, negligible morphological change was 
noted in glioblastoma line U-87, breast cancer line MDA-
MB-435, osteosarcoma line HOS, melanoma line SK-MEL5, 
colorectal cancer line COLO205, and prostate cancer line 
PC3. In these studies expression of GFP and/or CPE does 
not absolutely correlate with the production of mature virus. 
Fig. (1). UV fluorescent microscopy of TPV-GFP infected cancer cells at 7 days post infection. Left panels in each case show cell 
monolayers under visible light. Right panels show same area under UV fluorescence. Uninfected cells (MOCK) show no green fluorescence 
while TPV-GFP infected plaques emit green fluorescence. Greater progression of TPV-GFP infection is observed in U-373, HCT-116, 
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However, the titration of infectious virions does indicate the 
degree of virus productivity. 
  Initial green fluorescence observed in all infected human 
cancer cell lines tested indicates that TPV successfully 
penetrates all types of cells. Poxviruses enter the host cell 
through ubiquitous surface receptors like heparan sulfate, 
chondroitin sulfate and glycosaminoglycans, and this could 
explain the penetration of TPV and subsequent expression of 
early proteins including the green fluorescent protein [16, 
17]. Poxviruses are equipped with their own replication 
machinery for mRNA synthesis and DNA replication, and 
since the GFP gene is regulated by a synthetic early/late 
promoter, it will express GFP at all stages of replication. 
However, TPV is not able to produce as many infectious 
progeny in several cell lines as efficiently as that seen in 
OMK cells. These results suggest that TPV-GFP replication 
in cell lines such as SK-MEL5, T-47D, and HOS could be 
abortive. This could be due to required factors that are 
missing or factors already present that abort the replication 
of TPV at later steps of the virus replication cycle. One 
possibility could be caused by an inability of infectious 
mature virus to exit the host cell to spread to nearby cells. 
The question that the degree of virus replication in a specific 
cell line is related to a specific stage of virus replication, like 
virus entry or virus uncoating remains open. 
  Despite the many similarities in gene homology and 
genomic organization between TPV and VV, the proteins in 
TPV are more closely related to myxoma virus than to VV 
[18] as determined from the fully sequenced genome of TPV 
and myxoma virus [19]. Myxoma virus is from the genus 
Leporipoxvirus and is host-restricted to rabbits, causing the 
highly lethal myxomatosis disease in European rabbits [3]. 
This virus has become of significant interest to humans as 
recent studies have shown that myxoma virus displays 
oncolytic properties in human cancers. This predilection 
towards cancer cells is attributed to the innate dysregulated 
intracellular signaling pathway of these abnormal cells [20]; 
specifically, the amplification and overexpression of a 
particular group of serine/threonine protein kinases 
belonging to the protein kinase B (PKB) family [21]. Three 
of these protein kinases AKT1, AKT2, and AKT3 within the 
AKT family, are highly conserved cellular homologues that 
are involved in a multitude of cellular growth functions such 
as inhibition of apoptosis [22], proliferation, cell 
metabolism, and possibly angiogenesis [23]. Constitutively 
activated/hyperactivated AKT is involved in oncogenesis 
[24] as cells cease to enter the quiescent phase of the cell 
cycle, resulting in non-stop cell proliferation. 
  One of the myxoma host range proteins, M-T5, binds to 
and activates Akt [25], which subsequently inhibits the 
mammalian Target of Rapamycin (mTOR) complex [26], 
allowing the virus to replicate within the cell. Similar to TPV 
host range proteins, M-T5 also contains ankyrin repeats. 
Myxoma virus has been shown to replicate in myriad 
glioblastoma cell lines that possess a higher basal level of 
endogenous phosphorylated Akt [26-29]. Besides 
glioblastoma cells, human pancreatic adenocarcinoma cell 
lines with this same abnormality were also found to be 
permissive to myxoma virus infection [30]. Non-permissive 
tumor cells can be modified to become susceptible to 
myxoma infection simply by activating Akt expression [31]. 
  TPV is armed with a variety of potential immunomodula-
tory proteins such as Tumor Necrosis Factor binding, 
chemokine inhibitors, apoptosis inhibitors, complement 
inhibition, and other useful mechanisms to avoid and attack 
the host response to infection [14]. Nazarian et al. (2007) 
provided evidence that TPV also has many proteins showing 
ankyrin repeats and a 19L Kelch protein. Ankyrin repeats, 
like Kelch motifs mediate protein-protein interactions and 
suggests the same role for these uncharacterized proteins in 
TPV [32]. 
  However, results from myxoma virus [31] do not 
correlate with results described here for TPV in terms of cell 
permissiveness to virus due to endogenous Akt. TPV-GFP 
replicates poorly in HOS cells that contain high endogenous 
and phosphorylated Akt, whereas myxoma virus replicates 
well in this osteosarcoma cell line [31]. Another difference is 
the MDA-MB-435 breast cancer cells with no detectable 
levels of phosphorylated Akt, yet is still permissive to TPV-
GFP replication [31]. 
  It would be interesting to examine the susceptibility of 
human tumors to TPV in vivo since poxviruses are limited by 
their virulence genes, which are not always essential for 
replication in cell culture, but necessary to produce disease 
in an animal. Even though TPV is able to replicate in African 
green monkey kidney cell lines, it cannot cause an infection 
in African green monkeys [8, 33]. These experiments would 
give us great insight on the in vivo host range of TPV. 
  Several poxviruses, (e.g. YLDV, VV and myxoma virus) 
have been evaluated for their ability to replicate in cancerous 
cells of human origin. Results from these studies indicate 
that these cancer killing viruses, or oncolytic viruses, are 
able to preferentially target these aberrant cells, suggesting 
that TPV could also possess anti-cancer abilities [30, 34]. 
VV has progressed the furthest, of all the oncolytic 
poxviruses, and is currently undergoing clinical trials. 
  TPV would be a good candidate to be developed into an 
oncolytic virus because it is serologically distinct from VV 
and variola virus the causative agent of smallpox [1]. Thus, 
individuals vaccinated against smallpox with VV can still be 
treated with oncolytic TPV since it will not be subjected to 
immune clearance by the vast majority of the human 
population by VV specific antibodies. 
  We have previously shown that TPV replication in OMK 
cells is comparable to that in normal human fetal lung cells, 
WI-38 [12]. The results obtained from the current study 
provide a good foundation for subsequent experiments to 
illuminate the reasons for the increase in viral titer in certain 
cancer cell lines when compared to OMK cells. We are now 
in the process of inducing human xenograft tumors in nude 
mice to duplicate results presented here. In such studies the 
virus does not have to cross the blood brain barrier. 
However, wild type TPV is known to replicate in monocytes 
and macrophages that are capable of crossing the blood brain 
barrier. 
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